Abstract
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19- leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from recognition by and conferring resistance to CTL019.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antigens, CD19 / immunology*
-
Antigens, CD19 / therapeutic use
-
B-Lymphocytes / immunology
-
Cell- and Tissue-Based Therapy
-
Drug Resistance, Neoplasm / immunology*
-
Epitopes / immunology*
-
Humans
-
Leukemia / drug therapy*
-
Leukemia / immunology
-
Leukemia / pathology
-
Male
-
Receptors, Antigen, T-Cell / immunology
-
Receptors, Antigen, T-Cell / therapeutic use
-
Receptors, Chimeric Antigen
-
T-Lymphocytes / immunology
-
Young Adult
Substances
-
Antigens, CD19
-
CD19 molecule, human
-
Epitopes
-
Receptors, Antigen, T-Cell
-
Receptors, Chimeric Antigen
-
tisagenlecleucel